- Knight (GUD) has assumed full commercial activities for oral AKYNZEO in Canada
- AKYNZEO (netupitant/palonosetron capsules) is approved in Canada to prevent nausea and vomiting from chemotherapy and other emetogenic cancer therapies
- According to IQVIA, sales of AKYNZEO in Canada and Brazil were approximately $7 million in 2021
- Knight Therapeutics is a specialty pharmaceutical company focused on acquiring or licensing products for Canada and Latin America
- Knight Therapeutics (GUD) is unchanged, trading at $5.40 per share
Knight (GUD) has assumed full commercial activities for oral AKYNZEO in Canada.
AKYNZEO (netupitant/palonosetron capsules) is approved in Canada to prevent nausea and vomiting from chemotherapy and other emetogenic cancer therapies.
A single dose of AKYNZEO with dexamethasone prior to chemotherapy has been shown to prevent nausea and vomiting for up to five days.
Knight and Helsinn Healthcare entered into an exclusive license, distribution and supply agreement for oral/IV AKYNZEO in Canada, Brazil, Argentina, Uruguay and Paraguay, and ALOXI oral/IV in Canada in May 2022.
According to IQVIA, sales of AKYNZEO in Canada and Brazil were approximately $7 million in 2021.
“We are excited to take over the Canadian commercialization of AKYNZEO, an innovative once-per-cycle fixed-dose, dual combination antiemetic,” stated Samira Sakhia, Knight’s President and CEO. “AKYNZEO builds upon Knight’s growing Canadian oncology portfolio, increasing our presence in this important therapeutic area.”
Knight Therapeutics is a specialty pharmaceutical company focused on acquiring or licensing products for Canada and Latin America.
Knight Therapeutics (GUD) is unchanged, trading at $5.40 per share as of 1:44 pm ET.
